Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd has announced successful completion of a Phase 1b/2 trial for bisantrene, showing a promising 40% response rate in advanced acute myeloid leukaemia (AML) patients, thus surpassing their efficacy goals. The study, conducted in Israel, not only met its primary endpoint but also sets the stage for further AML studies with bisantrene. The company expresses gratitude towards the participants and plans to support subsequent clinical trials.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.
